KR20190111949A - Nrf2 활성화제 - Google Patents
Nrf2 활성화제 Download PDFInfo
- Publication number
- KR20190111949A KR20190111949A KR1020197022052A KR20197022052A KR20190111949A KR 20190111949 A KR20190111949 A KR 20190111949A KR 1020197022052 A KR1020197022052 A KR 1020197022052A KR 20197022052 A KR20197022052 A KR 20197022052A KR 20190111949 A KR20190111949 A KR 20190111949A
- Authority
- KR
- South Korea
- Prior art keywords
- carbonitrile
- alkyl
- phenyl
- dioxo
- tetrahydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- ZRFXAOXSSXSMRI-UHFFFAOYSA-N CCCC(CC)C(N)=O Chemical compound CCCC(CC)C(N)=O ZRFXAOXSSXSMRI-UHFFFAOYSA-N 0.000 description 2
- 0 C*CCC(C)([C@](CCCN(C1)C(C)=O)[C@]1(C)C=C1C#N)C1=O Chemical compound C*CCC(C)([C@](CCCN(C1)C(C)=O)[C@]1(C)C=C1C#N)C1=O 0.000 description 1
- YJOJHUSKDWBITM-QGZVFWFLSA-N CC(C)(C([C@@](C)(C1)C=C2C#N)=CCN1c1ncccn1)C2=O Chemical compound CC(C)(C([C@@](C)(C1)C=C2C#N)=CCN1c1ncccn1)C2=O YJOJHUSKDWBITM-QGZVFWFLSA-N 0.000 description 1
- OLHNCEZAWPNKAO-XMMPIXPASA-N CC(C)(C([C@@]1(C=C2C#N)c3ccccc3)=CCN(Cc3cccnc3)C1=O)C2=O Chemical compound CC(C)(C([C@@]1(C=C2C#N)c3ccccc3)=CCN(Cc3cccnc3)C1=O)C2=O OLHNCEZAWPNKAO-XMMPIXPASA-N 0.000 description 1
- YJOJHUSKDWBITM-KRWDZBQOSA-N CC(C)(C([C@](C)(C1)C=C2C#N)=CCN1c1ncccn1)C2=O Chemical compound CC(C)(C([C@](C)(C1)C=C2C#N)=CCN1c1ncccn1)C2=O YJOJHUSKDWBITM-KRWDZBQOSA-N 0.000 description 1
- PHWNXDBVZAXRPZ-INIZCTEOSA-N CC(C)(C([C@]1(C=C2C#N)P)=CCN(c3c[n](C)nc3)C1=N)C2=O Chemical compound CC(C)(C([C@]1(C=C2C#N)P)=CCN(c3c[n](C)nc3)C1=N)C2=O PHWNXDBVZAXRPZ-INIZCTEOSA-N 0.000 description 1
- OPSNTOVGNMHMJZ-INIZCTEOSA-N CC(C)(C([C@]1(C=C2C#N)P)=CCN(c3ccn[n]3C)C1=O)C2=O Chemical compound CC(C)(C([C@]1(C=C2C#N)P)=CCN(c3ccn[n]3C)C1=O)C2=O OPSNTOVGNMHMJZ-INIZCTEOSA-N 0.000 description 1
- OLHNCEZAWPNKAO-DEOSSOPVSA-N CC(C)(C([C@]1(C=C2C#N)c3ccccc3)=CCN(Cc3cccnc3)C1=O)C2=O Chemical compound CC(C)(C([C@]1(C=C2C#N)c3ccccc3)=CCN(Cc3cccnc3)C1=O)C2=O OLHNCEZAWPNKAO-DEOSSOPVSA-N 0.000 description 1
- MXUNJPDZLGARLB-UHFFFAOYSA-N CC(C)(C1(CCC23c4ccccc4)OCCO1)C2=CCNC3=O Chemical compound CC(C)(C1(CCC23c4ccccc4)OCCO1)C2=CCNC3=O MXUNJPDZLGARLB-UHFFFAOYSA-N 0.000 description 1
- ZWLWVFCWFFNHSL-UHFFFAOYSA-N CC(C)(C1=CCNCC1(C)C=C1C#N)C1=O Chemical compound CC(C)(C1=CCNCC1(C)C=C1C#N)C1=O ZWLWVFCWFFNHSL-UHFFFAOYSA-N 0.000 description 1
- UYGFVQUGADZYCE-IINYFYTJSA-N CC(C)([C@H](CC1)[C@](C)(C2)CNC1=O)c1c2cn[o]1 Chemical compound CC(C)([C@H](CC1)[C@](C)(C2)CNC1=O)c1c2cn[o]1 UYGFVQUGADZYCE-IINYFYTJSA-N 0.000 description 1
- DHWSZDQJPLBPJG-XJKSGUPXSA-N CC(C)([C@H](CCC1)[C@](C)(C2)CN1C(C)=O)C(O)=C2C#N Chemical compound CC(C)([C@H](CCC1)[C@](C)(C2)CN1C(C)=O)C(O)=C2C#N DHWSZDQJPLBPJG-XJKSGUPXSA-N 0.000 description 1
- SUHJQRIEXOWASH-XJKSGUPXSA-N CC(C)([C@H](CCC1)[C@](C)(C2)CN1C(C)=O)c1c2cn[o]1 Chemical compound CC(C)([C@H](CCC1)[C@](C)(C2)CN1C(C)=O)c1c2cn[o]1 SUHJQRIEXOWASH-XJKSGUPXSA-N 0.000 description 1
- PATJZLOMDYCPAC-NKUHCKNESA-N CC(C)([C@H](CCNC1)C1(C)C=C1C#N)C1=O Chemical compound CC(C)([C@H](CCNC1)C1(C)C=C1C#N)C1=O PATJZLOMDYCPAC-NKUHCKNESA-N 0.000 description 1
- ZCXUUULAHNSMAN-SMDDNHRTSA-N CC(C)([C@H]1[C@](C)(C2)CNCCC1)c1c2cn[o]1 Chemical compound CC(C)([C@H]1[C@](C)(C2)CNCCC1)c1c2cn[o]1 ZCXUUULAHNSMAN-SMDDNHRTSA-N 0.000 description 1
- CNQCWYFDIQSALX-UHFFFAOYSA-N ClCc1cccnc1 Chemical compound ClCc1cccnc1 CNQCWYFDIQSALX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439289P | 2016-12-27 | 2016-12-27 | |
| US62/439,289 | 2016-12-27 | ||
| PCT/US2017/068455 WO2018125880A1 (en) | 2016-12-27 | 2017-12-27 | Nrf2 activator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190111949A true KR20190111949A (ko) | 2019-10-02 |
Family
ID=61007836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197022052A Withdrawn KR20190111949A (ko) | 2016-12-27 | 2017-12-27 | Nrf2 활성화제 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10968181B2 (https=) |
| EP (2) | EP3875450A1 (https=) |
| JP (1) | JP7088933B2 (https=) |
| KR (1) | KR20190111949A (https=) |
| CN (1) | CN110382475A (https=) |
| AR (1) | AR110590A1 (https=) |
| AU (1) | AU2017387070B2 (https=) |
| BR (1) | BR112019013341A2 (https=) |
| CA (1) | CA3048849A1 (https=) |
| CL (1) | CL2019001804A1 (https=) |
| CO (1) | CO2019008110A2 (https=) |
| CR (1) | CR20190344A (https=) |
| EA (1) | EA201991595A1 (https=) |
| ES (1) | ES2878102T3 (https=) |
| IL (1) | IL267692B (https=) |
| JO (1) | JOP20190163B1 (https=) |
| MX (1) | MX2019007826A (https=) |
| PE (1) | PE20191488A1 (https=) |
| TW (1) | TW201827406A (https=) |
| UY (1) | UY37551A (https=) |
| WO (1) | WO2018125880A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230021505A (ko) | 2021-08-05 | 2023-02-14 | 주식회사 엘씨에스바이오텍 | 신규한 곡류 발효물, 그 곡류 발효물의 피부 보호 용도, 피부 유용 물질 스크리닝 방법 및 산화적 스트레스로 인한 피부 손상 예측 방법 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2963613T3 (es) * | 2018-10-22 | 2024-04-01 | C4X Discovery Ltd | Compuestos terapéuticos |
| MX2021006527A (es) | 2018-12-05 | 2021-07-21 | Scohia Pharma Inc | Compuesto macrociclico y su uso. |
| CN112679328B (zh) * | 2019-10-17 | 2023-09-15 | 南京药石科技股份有限公司 | 一种3-三氟甲基-2-环己烯-1-酮的工业化生产方法 |
| WO2024091523A1 (en) * | 2022-10-24 | 2024-05-02 | 2A Biosciences, Inc. | Conformationally restricted phenethylamine analogs |
| CN119735636A (zh) * | 2024-09-06 | 2025-04-01 | 五邑大学 | 一种四环肽中间体化合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JP2008110962A (ja) * | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| CA2721665C (en) * | 2008-04-18 | 2017-01-24 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| WO2011156889A1 (en) * | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| EP2678305A4 (en) * | 2011-02-25 | 2015-11-04 | Univ Johns Hopkins | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS |
| WO2016065264A1 (en) * | 2014-10-24 | 2016-04-28 | Biogen Ma Inc. | Diterpenoid derivatives and methods of use thereof |
| CA2988373A1 (en) * | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
-
2017
- 2017-12-26 UY UY0001037551A patent/UY37551A/es unknown
- 2017-12-26 AR ARP170103684A patent/AR110590A1/es unknown
- 2017-12-27 CN CN201780087398.9A patent/CN110382475A/zh active Pending
- 2017-12-27 EP EP21152411.1A patent/EP3875450A1/en not_active Withdrawn
- 2017-12-27 JP JP2019535363A patent/JP7088933B2/ja not_active Expired - Fee Related
- 2017-12-27 BR BR112019013341A patent/BR112019013341A2/pt not_active IP Right Cessation
- 2017-12-27 US US16/473,667 patent/US10968181B2/en active Active
- 2017-12-27 MX MX2019007826A patent/MX2019007826A/es unknown
- 2017-12-27 WO PCT/US2017/068455 patent/WO2018125880A1/en not_active Ceased
- 2017-12-27 CR CR20190344A patent/CR20190344A/es unknown
- 2017-12-27 KR KR1020197022052A patent/KR20190111949A/ko not_active Withdrawn
- 2017-12-27 CA CA3048849A patent/CA3048849A1/en active Pending
- 2017-12-27 ES ES17832681T patent/ES2878102T3/es active Active
- 2017-12-27 TW TW106146033A patent/TW201827406A/zh unknown
- 2017-12-27 PE PE2019001341A patent/PE20191488A1/es unknown
- 2017-12-27 AU AU2017387070A patent/AU2017387070B2/en not_active Ceased
- 2017-12-27 EP EP17832681.5A patent/EP3562816B1/en active Active
- 2017-12-27 EA EA201991595A patent/EA201991595A1/ru unknown
- 2017-12-27 JO JOP/2019/0163A patent/JOP20190163B1/ar active
-
2019
- 2019-06-27 IL IL267692A patent/IL267692B/en unknown
- 2019-06-27 CL CL2019001804A patent/CL2019001804A1/es unknown
- 2019-07-26 CO CONC2019/0008110A patent/CO2019008110A2/es unknown
-
2021
- 2021-04-02 US US17/221,358 patent/US20210340107A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230021505A (ko) | 2021-08-05 | 2023-02-14 | 주식회사 엘씨에스바이오텍 | 신규한 곡류 발효물, 그 곡류 발효물의 피부 보호 용도, 피부 유용 물질 스크리닝 방법 및 산화적 스트레스로 인한 피부 손상 예측 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019001804A1 (es) | 2019-11-15 |
| EP3875450A1 (en) | 2021-09-08 |
| IL267692B (en) | 2021-09-30 |
| ES2878102T3 (es) | 2021-11-18 |
| WO2018125880A8 (en) | 2019-06-06 |
| US10968181B2 (en) | 2021-04-06 |
| US20210340107A1 (en) | 2021-11-04 |
| UY37551A (es) | 2018-07-31 |
| WO2018125880A1 (en) | 2018-07-05 |
| JP2020503332A (ja) | 2020-01-30 |
| EP3562816B1 (en) | 2021-01-20 |
| US20190345112A1 (en) | 2019-11-14 |
| AR110590A1 (es) | 2019-04-10 |
| EP3562816A1 (en) | 2019-11-06 |
| JP7088933B2 (ja) | 2022-06-21 |
| JOP20190163A1 (ar) | 2019-06-27 |
| MX2019007826A (es) | 2019-10-24 |
| CN110382475A (zh) | 2019-10-25 |
| PE20191488A1 (es) | 2019-10-21 |
| CO2019008110A2 (es) | 2019-08-20 |
| CA3048849A1 (en) | 2018-07-05 |
| AU2017387070B2 (en) | 2022-03-24 |
| IL267692A (en) | 2019-08-29 |
| EA201991595A1 (ru) | 2020-01-27 |
| JOP20190163B1 (ar) | 2023-09-17 |
| TW201827406A (zh) | 2018-08-01 |
| AU2017387070A1 (en) | 2019-08-15 |
| BR112019013341A2 (pt) | 2019-12-24 |
| CR20190344A (es) | 2019-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190111949A (ko) | Nrf2 활성화제 | |
| AU2015236982B2 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| ES3005265T3 (en) | Pyrazole magl inhibitors | |
| EP3833662B1 (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| JP2024517906A (ja) | スルホンイミドイル含有ａｔｒ阻害剤化合物 | |
| EP3405465A1 (en) | Irak4 inhibiting agents | |
| US20240279197A1 (en) | Nrf2 activator | |
| WO2019115774A1 (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| WO2016007534A1 (en) | Therapeutic compounds and methods of use thereof | |
| EP3573968A1 (en) | Nrf2 activator | |
| CN120882732A (zh) | 负nmda调节化合物和其使用方法 | |
| JP7627269B2 (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| CA3228249A1 (en) | Nitrogen-containing tricyclic compound and pharmaceutical use thereof | |
| HK40060901A (en) | Nrf2 activator | |
| IL303931A (en) | History of 2H-indazole as IRAK4 inhibitors and their use to treat diseases | |
| NZ755789A (en) | Nrf2 activator | |
| HK40017131B (en) | Nrf2 activator | |
| HK40017131A (en) | Nrf2 activator | |
| WO2026090509A1 (en) | Spiro heterocyclic cdk2 inhibitors | |
| JP2026062559A (ja) | テトラヒドロピロロピリミジノン化合物及びその医薬用途 | |
| WO2017222083A1 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190726 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201224 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20211109 |
|
| WITB | Written withdrawal of application |